<span id="midArticle_start"/>May 25 Biotie Therapies Oyj :
<span id="midArticle_0"/>* Says has reached agreement with the U.S. Food and DrugAdministration (FDA) on a Special Protocol Assessment (SPA)for the Phase 3 study of tozadenant in Parkinson's disease(PD)
<span id="midArticle_1"/> <span class="first-article-divide"/>* Says Phase 3 study (TOZ-PD) will evaluate efficacy andsafety of tozadenant compared to placebo in PD patients takinglevodopa and experiencing end-of-dose wearing offSource text for Eikon:
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_3"/>
<span id="midArticle_0"/>* Says has reached agreement with the U.S. Food and DrugAdministration (FDA) on a Special Protocol Assessment (SPA)for the Phase 3 study of tozadenant in Parkinson's disease(PD)
<span id="midArticle_1"/> <span class="first-article-divide"/>* Says Phase 3 study (TOZ-PD) will evaluate efficacy andsafety of tozadenant compared to placebo in PD patients takinglevodopa and experiencing end-of-dose wearing offSource text for Eikon:
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_3"/>
via Smart Health Shop Forum http://ift.tt/1IUHtxf
No comments:
Post a Comment